Study Finds AstraZeneca Vaccine<br />to Be 79 Percent Efficient Against<br />Symptomatic COVID-19.<br />On Monday, results were announced from a late-stage<br />study on AstraZeneca’s COVID-19 vaccine, AZD1222. .<br />The phase 3 trial involved<br />over 32,000 participants.<br />AstraZeneca’s vaccine<br />displayed a 79 percent efficacy<br />at preventing symptomatic<br />cases of COVID-19. .<br />Although that efficacy was consistent across all ages<br />and ethnicities, it was shown to reach 80 percent in<br />those 65 years of age and older.<br />The vaccine also showed<br />100 percent efficacy at<br />preventing hospitalization<br />and severe disease<br />due to COVID-19.<br />The trial did not find<br />any safety concerns<br />related to the vaccine,<br />such as an increased<br />risk for blood clots. .<br />These findings reconfirm previous<br />results observed in AZD1222 trials<br />across all adult populations but it’s<br />exciting to see similar efficacy results<br />in people over 65 for the first time … , Ann Falsey, Professor of Medicine at the University of<br />Rochester School of Medicine.<br />AstraZeneca is reportedly planning to apply for emergency use authorization from the U.S. Food and Drug Administration sometime in early April. .<br />If approved, it will be the fourth COVID-19<br />vaccine offered in the United States
